Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
D 277.96 -1.09% -3.07
ARGX closed down 1.09 percent on Friday, April 9, 2021, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Flat
Historical ARGX trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Gapped Down Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -1.09%
Narrow Range Bar Range Contraction -1.09%
NR7 Range Contraction -1.09%
NR7-2 Range Contraction -1.09%
Older End-of-Day Signals for ARGX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 19 hours ago
60 Minute Opening Range Breakout about 20 hours ago
200 DMA Support about 21 hours ago
Down 2 % about 22 hours ago
Down 1% about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

argenx SE Description

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Inflammation Lymphoma Cancer Immunotherapy Autoimmune Disease Acute Myeloid Leukemia Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Dyslipidemia Hematological Cancers Myasthenia Myasthenia Gravis Thrombocytopenia Janus Kinase Inhibitor Rgx Skin Inflammation Tolerx Treatment Of Hematological Cancers

Is ARGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 382.15
52 Week Low 130.0
Average Volume 211,381
200-Day Moving Average 275.39
50-Day Moving Average 320.19
20-Day Moving Average 291.91
10-Day Moving Average 279.08
Average True Range 10.26
ADX 29.85
+DI 17.26
-DI 31.61
Chandelier Exit (Long, 3 ATRs ) 290.43
Chandelier Exit (Short, 3 ATRs ) 299.45
Upper Bollinger Band 322.39
Lower Bollinger Band 261.43
Percent B (%b) 0.27
BandWidth 20.88
MACD Line -10.99
MACD Signal Line -11.29
MACD Histogram 0.3007
Fundamentals Value
Market Cap 13.09 Billion
Num Shares 47.1 Million
EPS -1.73
Price-to-Earnings (P/E) Ratio -161.14
Price-to-Sales 193.85
Price-to-Book 6.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 284.67
Resistance 3 (R3) 284.35 281.81 283.55
Resistance 2 (R2) 281.81 280.10 281.96 283.17
Resistance 1 (R1) 279.88 279.04 280.85 280.20 282.80
Pivot Point 277.34 277.34 277.82 277.49 277.34
Support 1 (S1) 275.41 275.63 276.38 275.73 273.12
Support 2 (S2) 272.87 274.57 273.02 272.75
Support 3 (S3) 270.94 272.87 272.37
Support 4 (S4) 271.26